

Epclusa® (sofosbuvir/velpatasvir) – Expanded indication

- On August 1, 2017, <u>Gilead announced</u> the FDA approval of <u>Epclusa (sofosbuvir/velpatasvir)</u> tablets, to include use in patients co-infected with the hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1).
- Epclusa is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6
 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis in
 combination with ribavirin.
- The expanded approval of Epclusa was supported by data from the ASTRAL-5 study, which
 evaluated 12 weeks of treatment with Epclusa in 106 patients with HCV/HIV co-infection and on
 stable HIV antiretroviral therapy.
 - Overall, 95% of patients achieved a sustained virologic response, defined as an undetectable viral load 12 weeks after completing therapy.
 - No patients had HIV rebound during treatment and CD4+ counts were stable during treatment.
- Epclusa carries a boxed warning regarding the risk of hepatitis B virus (HBV) reactivation in HCV/HBV co-infected patients.
- The safety profile of Epclusa in HCV/HIV co-infected patients was similar to that observed in HCV
 mono-infected patients. The most common adverse events (≥ 10%) with Epclusa use were fatigue
 and headache.
- The recommended dose of Epclusa is one tablet orally once daily for 12 weeks. See table below.

Patient Population	Treatment Regimen and Duration
Treatment-naïve and treatment- experienced* without cirrhosis and with compensated cirrhosis (Child-Pugh A)	Epclusa 12 weeks
Treatment-naïve and treatment- experienced* with decompensated cirrhosis (Child-Pugh B or C)	Epclusa plus ribavirin 12 weeks

^{*} In clinical trials, regimens contained peginterferon alfa/ribavirin with or without an HCV NS3/4 protease inhibitor

 For additional information, including dosing in other populations, refer to the Epclusa drug label.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.